Aptargroup reports $1.02 billion revenue for Q3 2026

Cover page 3 changes

3 unchanged paragraphs

FOR THE QUARTERLY PERIOD ENDED JUNE SEPTEMBER 30, 2026

16 unchanged paragraphs

The number of shares outstanding of common stock, as of July 27, October 26, 2026, was 63,581,129 63,388,980 shares.

Quarter Ended June September 30, 2026

1 unchanged paragraph

Financial statements (unaudited) 229 changes

2 unchanged paragraphs

June 30, Six Months Ended

Net Sales $ 1,026,508 $ 966,009 $ 2,009,376 $ 1,853,314

Selling, research & development and administrative 157,735 151,139 325,337 306,416

Depreciation and amortization 79,641 69,904 155,366 135,551

Restructuring initiatives 1,419 1,579 2,505 3,621

Total Operating Expenses 899,786 821,616 1,775,158 1,595,473

Operating Income 126,722 144,393 234,218 257,841

September 30, Nine Months Ended

Net Sales $ 1,019,119 $ 961,131 $ 3,028,495 $ 2,814,445

Cost of sales (exclusive of depreciation and amortization shown below) 660,991 598,994 1,291,950 1,149,885 646,196 598,046 1,938,146 1,747,931

Selling, research & development and administrative 160,164 148,760 485,501 455,176

Depreciation and amortization 75,544 75,234 230,910 210,785

Restructuring initiatives 2,208 2,168 4,713 5,789

Total Operating Expenses 884,112 824,208 2,659,270 2,419,681

Operating Income 135,007 136,923 369,225 394,764

1 unchanged paragraph

Interest expense ( 16,001 ) ( 10,850 ) ( 32,943 ) ( 22,201 )

Interest income 2,787 1,880 6,429 4,694

Net investment gain (loss) 937 2,102 ( 149 ) 1,006

Equity in results of affiliates 1,404 2,309 2,118 4,395

Miscellaneous expense, net ( 802 ) ( 120 ) ( 855 ) ( 6 )

Total Other (Expense) Income

Income before Income Taxes 115,047 139,714 208,818 245,729

Provision for Income Taxes 27,037 27,982 48,041 55,334

Net Income $ 88,010 $ 111,732 $ 160,777 $ 190,395

Net Income Attributable to AptarGroup, Inc. $ 87,573 $ 111,720 $ 160,247 $ 190,518

Interest expense ( 15,790 ) ( 13,532 ) ( 48,733 ) ( 35,733 )

Interest income 1,930 2,400 8,359 7,094

Net investment (loss) gain ( 1,011 ) ( 161 ) ( 1,160 ) 845

Loss on Russia deconsolidation ( 58,020 ) ( 58,020 )

Equity in results of affiliates 1,106 1,747 3,224 6,142

Gain from remeasurement of equity method investment 26,518 26,518

Miscellaneous (expense) income, net ( 2,889 ) 232 ( 3,744 ) 226 ( 74,674 ) 17,204 ( 100,074 ) 5,092

Income before Income Taxes 60,333 154,127 269,151 399,856

Provision for Income Taxes 27,511 26,295 75,552 81,629

Net Income $ 32,822 $ 127,832 $ 193,599 $ 318,227

Net (Income) Loss Attributable to Noncontrolling Interests ( 152 226 ) ( 12 47 ) ( 156 382 ) 123 76

Net Loss (Income) Attributable to Redeemable Noncontrolling Interests ( 285 ) 6 142 ( 374 368 ) 142

Net Income Attributable to AptarGroup, Inc. $ 32,602 $ 127,927 $ 192,849 $ 318,445

1 unchanged paragraph

Basic $ 1.38 $ 1.69 $ 2.51 $ 2.88

Diluted $ 1.36 $ 1.67 $ 2.48 $ 2.83

Basic $ 0.51 $ 1.95 $ 3.03 $ 4.83

Diluted $ 0.51 $ 1.92 $ 3.00 $ 4.75

1 unchanged paragraph

Basic 63,634 65,995 63,841 66,132

Diluted 64,208 67,048 64,504 67,262

Basic 63,523 65,709 63,733 65,989

Diluted 64,147 66,630 64,373 67,043

Dividends per Common Share $ 0.48 $ 0.45 $ 0.96 1.44 $ 0.90 1.35

2 unchanged paragraphs

June 30, Six Months Ended

Other Comprehensive (Loss) Income:

Foreign currency translation adjustments ( 10,516 ) 162,756 ( 30,267 ) 245,117

September 30, Nine Months Ended

Net Income Attributable to AptarGroup, Inc. and Noncontrolling Interests $ 87,725 32,828 $ 111,732 127,974 $ 160,403 193,231 $ 190,395 318,369

Other Comprehensive Income (Loss):

Foreign currency translation adjustments ( 645 ) ( 3,456 ) ( 30,912 ) 238,148

Changes in derivative gains (losses), net of tax 1,890 ( 14,138 ) 5,956 2,534 1,415 8,490 ( 18,005 16,590 )

1 unchanged paragraph

Actuarial (loss) gain, net of tax ( 82 ) 46 3,409 114

Total other comprehensive (loss) income ( 8,589 ) 148,813 ( 20,674 ) 227,507

Comprehensive Income 79,136 260,545 139,729 417,902

Comprehensive Income Attributable to AptarGroup, Inc. $ 78,768 $ 256,829 $ 139,184 $ 414,246

Actuarial gain, net of tax 96 230 3,505 344

Amortization of prior service cost included in net income, net of tax ( 49 ) 133 40 246 19 138 59 384

Amortization of net loss included in net income, net of tax 168 16 188 35 12 19 200 54

Total defined benefit pension plan, net of tax 37 195 3,637 395 127 387 3,764 782

Total other comprehensive income (loss) 2,016 ( 1,654 ) ( 18,658 ) 222,340

Comprehensive Income 34,844 126,320 174,573 540,709

Comprehensive Income Attributable to Noncontrolling Interests ( 368 381 ) ( 3,716 139 ) ( 545 926 ) ( 3,656 282 )

Comprehensive Income Attributable to AptarGroup, Inc. $ 34,463 $ 126,181 $ 173,647 $ 540,427

2 unchanged paragraphs

Inventories 580,136 537,845

Miscellaneous 153,225 152,713

June September 30, 2026 December 31, 2025

Cash and equivalents $ 190,402 204,176 $ 402,424

Short-term investments 6,864 8,121 7,109

Accounts and notes receivable, less current expected credit loss ( CECL ) of $ 16,995 18,403 in 2026 and $ 17,732 in 2025

Inventories 582,605 537,845

Prepaid and other 159,754 157,950 142,354

Total Current Assets 1,834,816 1,836,791 1,893,562

Buildings and improvements 884,910 885,017 885,936

Machinery and equipment 3,699,708 3,690,791 3,658,289

Property, Plant and Equipment, Gross 4,615,428 4,606,101 4,575,728

Less: Accumulated depreciation ( 2,969,447 2,970,571 ) ( 2,899,249 )

3 unchanged paragraphs

3 unchanged paragraphs

1 unchanged paragraph

2 unchanged paragraphs

4 unchanged paragraphs

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

3 unchanged paragraphs

1 unchanged paragraph

1 unchanged paragraph

2 unchanged paragraphs

3 unchanged paragraphs

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

2 unchanged paragraphs

2 unchanged paragraphs

and 149 more changes in the filing

Note 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 2 changes

3 unchanged paragraphs

For all periods presented through September 21, 2026, the operating results of our Russian subsidiary are included in our consolidated financial statements. As of September 21, 2026, we deconsolidated our Russia operations from our consolidated financial statements and recognized a loss on deconsolidation. See Note 20 - Deconsolidation for more information.

12 unchanged paragraphs

All outstanding amounts related to suppliers participating in the SCF are recorded within accounts payable, accrued and other liabilities in our Condensed Consolidated Balance Sheets, and associated payments are included in operating activities within our Condensed Consolidated Statements of Cash Flows. As of June September 30, 2026, the amounts due to suppliers participating in the SCF and included in accounts payable, accrued and other liabilities were approximately $ 36.5 million.

1 unchanged paragraph

Note 2: REVENUE 48 changes

Revenue by segment and geography based on shipped to locations for the three and six nine months ended June September 30, 2026 and 2025 were as follows:

For the Three Months Ended June September 30, 2026

1 unchanged paragraph

Pharma $ 230,731 $ 143,711 $ 19,554 $ 64,171 $ 458,167

Beauty 221,178 60,339 42,187 43,750 367,454

Closures 69,126 87,951 23,320 20,490 200,887

Total $ 521,035 $ 292,001 $ 85,061 $ 128,411 $ 1,026,508

Pharma $ 215,218 $ 151,570 $ 20,108 $ 67,074 $ 453,970

Beauty 215,133 58,037 44,755 39,447 357,372

Closures 71,072 89,959 24,507 22,239 207,777

Total $ 501,423 $ 299,566 $ 89,370 $ 128,760 $ 1,019,119

For the Three Months Ended June September 30, 2025

1 unchanged paragraph

Pharma $ 211,829 $ 161,162 $ 13,520 $ 56,078 $ 442,589

Beauty 205,236 56,832 42,907 29,874 334,849

Closures 58,930 91,755 19,715 18,171 188,571

Total $ 475,995 $ 309,749 $ 76,142 $ 104,123 $ 966,009

For the Six Months Ended June 30, 2026

Pharma $ 208,055 $ 157,606 $ 10,968 $ 68,781 $ 445,410

Beauty 196,137 57,012 42,132 32,487 327,768

Closures 61,611 85,110 22,031 19,201 187,953

Total $ 465,803 $ 299,728 $ 75,131 $ 120,469 $ 961,131

For the Nine Months Ended September 30, 2026

1 unchanged paragraph

Pharma $ 457,417 $ 285,165 $ 39,242 $ 114,903 $ 896,727

Beauty 444,054 117,108 88,466 81,461 731,089

Closures 130,414 169,534 43,320 38,292 381,560

Total $ 1,031,885 $ 571,807 $ 171,028 $ 234,656 $ 2,009,376

For the Six Months Ended June 30, 2025

Pharma $ 672,635 $ 436,735 $ 59,350 $ 181,977 $ 1,350,697

Beauty 659,187 175,145 133,221 120,908 1,088,461

Closures 201,486 259,493 67,827 60,531 589,337

Total $ 1,533,308 $ 871,373 $ 260,398 $ 363,416 $ 3,028,495

For the Nine Months Ended September 30, 2025

1 unchanged paragraph

Pharma $ 410,522 $ 302,823 $ 25,501 $ 113,210 $ 852,056

Beauty 393,145 115,029 82,493 49,889 640,556

Closures 110,974 174,354 40,662 34,712 360,702

Total $ 914,641 $ 592,206 $ 148,656 $ 197,811 $ 1,853,314

Pharma $ 618,577 $ 460,429 $ 36,469 $ 181,991 $ 1,297,466

Beauty 589,282 172,041 124,625 82,376 968,324

Closures 172,585 259,464 62,693 53,913 548,655

Total $ 1,380,444 $ 891,934 $ 223,787 $ 318,280 $ 2,814,445

2 unchanged paragraphs

Contract asset (current) $ 16,726 $ 11,600 $ 5,126

Contract liability (current) 79,525 74,827 4,698

Contract liability (long-term) 36,294 49,901 ( 13,607 )

Balance as of June September 30, 2026 Balance as of December 31, 2025 Increase/ (Decrease)

Contract asset (current) $ 13,717 $ 11,600 $ 2,117

Contract liability (current) 82,763 74,827 7,936

Contract liability (long-term) 38,931 49,901 ( 10,970 )

The differences in the opening and closing balances of our contract asset and contract liabilities are primarily the result of timing differences between our performance and the invoicing. The total amount of revenue recognized during the current period against contract liabilities is $ 82.6 103.9 million, including $ 47.6 57.7 million relating to contract liabilities at the beginning of the year. Current contract assets are included within Prepaid and other, while current contract liabilities and long-term contract liabilities are included within Accounts payable, accrued and other liabilities and Deferred and other non-current liabilities, respectively, within our Condensed Consolidated Balance Sheets.

7 unchanged paragraphs

In certain instances, we offer extended warranties on our tools above and beyond the normal standard warranties. We normally receive payment at the inception of the contract and recognize revenue over the term of the contract. We do not have any material extended warranties as of June September 30, 2026 or December 31, 2025.

5 unchanged paragraphs

Note 3: INVENTORIES 7 changes

1 unchanged paragraph

Raw materials $ 163,424 $ 152,574

Finished goods 219,931 191,095

Total $ 580,136 $ 537,845

Raw materials $ 154,630 $ 152,574

Work in process 196,781 197,979 194,176

Finished goods 229,996 191,095

Total $ 582,605 $ 537,845

Note 4: GOODWILL AND OTHER INTANGIBLE ASSETS 18 changes

The changes in the carrying amount of goodwill for the six nine months ended June September 30, 2026 by reporting segment were as follows:

2 unchanged paragraphs

Foreign currency exchange effects ( 7,167 ) ( 624 ) ( 441 ) ( 8,232 )

Balance as of June 30, 2026 $ 531,536 $ 370,224 $ 167,906 $ 1,069,666

Foreign currency exchange effects ( 9,541 ) ( 623 ) ( 582 ) ( 10,746 )

Balance as of September 30, 2026 $ 529,162 $ 370,225 $ 167,765 $ 1,067,152

The table below shows a summary of intangible assets as of June September 30, 2026 and December 31, 2025.

June September 30, 2026 December 31, 2025

2 unchanged paragraphs

Patents 12.5 $ 18,869 $ ( 4,687 ) $ 14,182 $ 19,032 $ ( 4,016 ) $ 15,016

Patents 12.3 $ 19,215 $ ( 5,205 ) $ 14,010 $ 19,032 $ ( 4,016 ) $ 15,016

Acquired technology 11.0 155,173 154,635 ( 104,338 107,204 ) 50,835 47,431 157,350 ( 99,551 ) 57,799

Customer relationships 11.7 330,957 330,424 ( 187,760 192,286 ) 143,197 138,138 332,088 ( 177,686 ) 154,402

Trademarks and trade names 4.7 46,293 3.1 46,316 ( 42,873 43,547 ) 3,420 2,769 46,885 ( 41,726 ) 5,159

License agreements and other 20.5 33,853 20.2 34,546 ( 11,748 12,368 ) 22,105 22,178 32,927 ( 9,964 ) 22,963

Total intangible assets 11.5 11.4 $ 585,145 585,136 $ ( 351,406 360,610 ) $ 233,739 224,526 $ 588,282 $ ( 332,943 ) $ 255,339

Aggregate amortization expense for the intangible assets above for the quarters ended June September 30, 2026 and 2025 was $ 11,159 10,293 and $ 11,087 11,542 , respectively. Aggregate amortization expense for the intangible assets above for the six nine months ended June September 30, 2026 and 2025 was $ 22,574 32,866 and $ 21,831 33,373 , respectively.

As of June September 30, 2026, future estimated amortization expense for the years ending December 31 is as follows:

2026 $ 22,173 11,081 (remaining estimated amortization for 2026)

Future amortization expense may fluctuate depending on changes in foreign currency rates. The estimates for amortization expense noted above are based upon foreign exchange rates as of June September 30, 2026.

Note 5: INCOME TAXES 5 changes

1 unchanged paragraph

The Organisation for Economic Co-operation and Development s Model Global Anti-Base Erosion rules under Pillar Two have been enacted by various countries beginning in 2024. These enacted laws relate to the Pillar Two safe harbors, Income Inclusion Rule, Qualified Domestic Minimum Top-up Tax and the Undertaxed Profits Rule for 2025 and onward. We have analyzed the provisions in the applicable jurisdictions and provided for the appropriate tax amounts. We do not expect a material impact from Pillar Two related taxes for 2026.

The effective tax rate for the three months ended June 30, 2026 and 2025, respectively, was 23.5 % and 20.0 %. The effective tax rate for the six months ended June 30, 2026 and 2025, respectively, was 23.0 % and 22.5 %. The effective tax rate for the three and six months ended June 30, 2026 did not include a deferred tax benefit from the release of a valuation allowance, and greater tax benefits from share-based compensation that existed in the prior-year period.

The effective tax rate for the three months ended September 30, 2026 and 2025, respectively, was 45.6 % and 17.1 %. The effective tax rate for the three months ended September 30, 2026, reflects a loss on the deconsolidation of our Russian subsidiary on September 21, 2026, which is not deductible for tax purposes ( 25.7 %). The effective tax rate for the three months ended September 30, 2025 reflects a benefit related to the gain from remeasurement of an equity investment upon consolidation ( 4.2 %), and a deferred tax benefit resulting from the release of a valuation allowance ( 2.7 %).

The effective tax rate for the nine months ended September 30, 2026 and 2025, was 28.1 % and 20.4 % respectively. The effective tax rate for the nine months ended September 30, 2026 reflects a negative 5.8 % tax impact from the loss on deconsolidation of our Russian subsidiary on September 21, 2026. The effective tax rate for the nine months ended September 30, 2025 reflects deferred tax benefits from valuation allowance releases ( 3.1 %), and a benefit related to the gain from remeasurement of an equity investment upon consolidation ( 1.6 %).

Given our current earnings and anticipated future earnings, we believe there is a reasonable possibility that within the next 12 months, sufficient positive evidence may become available to support the realization of $ 2.0 million to $ 5.0 6.0 million of deferred tax assets, for which there is currently a corresponding valuation allowance. Release of the valuation allowance would result in the recognition of certain deferred tax assets and a decrease to income tax expense for the period in which the release is recorded. However, the exact timing and amount of the valuation allowance release are subject to change pending the level of profitability that we are able to actually achieve.

Note 6: DEBT 18 changes

1 unchanged paragraph

At June September 30, 2026 and December 31, 2025, our short-term obligations, revolving credit facility and overdrafts consisted of the following:

Short-term obligations 2.57 2.48 % (1)

Revolving credit facility 3.54 3.84 % (1)

Overdraft 6.73 % (1)

(1) The rate represents the weighted-average interest rate as of June September 30, 2026.

We have a revolving credit facility (the revolving credit facility ) with a syndicate of banks that provides us with unsecured financing of up to $ 600.0 million, which may be increased by up to $ 300.0 million more, subject to the satisfaction of certain conditions. The revolving credit facility is available in the U.S. and to our wholly-owned UK subsidiary and could be drawn in various currencies including USD, EUR, GBP, and CHF. On July 2, 2024, we entered into a new amended and restated agreement (the amended revolving credit facility ) that extended the maturity date to July 2029, subject to a maximum of two one-year extensions in certain circumstances. As of June September 30, 2026, we had utilized $ 37.5 50.0 million and 130.0 million ($ 148.5 147.2 million) under the amended revolving credit facility in the U.S. and no balance was utilized by our wholly-owned UK subsidiary. As of December 31, 2025, 130.0 million ($ 152.6 million) was utilized under the amended revolving credit facility in the U.S. and no balance was utilized by our wholly-owned UK subsidiary.

1 unchanged paragraph

We also have an unsecured money market borrowing arrangement to provide short-term financing of up to $ 30.0 million that is available in the U.S. No borrowing on this facility is permitted over a quarter-end date. As such, no balance was outstanding under this arrangement as of June September 30, 2026 or December 31, 2025.

1 unchanged paragraph

On July 2, 2024, we entered into a term loan with a syndicate of banks (the Term Loan ). The Term Loan matures in July 2027. As of June September 30, 2026 and December 31, 2025, $ 116.2 million and $ 141.1 million, respectively, was utilized under the Term Loan. On February 26, 2026, we repaid in full the $ 125.0 million of 3.60 % Senior Notes that were due in February 2026.

At June September 30, 2026 and December 31, 2025, our long-term obligations consisted of the following:

June September 30, 2026 December 31, 2025

Notes payable 3.65 4.18 %, due in monthly and annual installments through 2035 (1)

1 unchanged paragraph

Term loan 4.97 5.30 % floating, due in 2027

2 unchanged paragraphs

Finance Lease Liabilities 23,436 22,444 25,339

Unamortized debt issuance costs ( 7,516 7,093 ) ( 8,346 )

Current maturities of long-term obligations ( 31,699 121,241 ) ( 159,584 )

Total long-term obligations $ 1,118,415 1,024,735 $ 1,139,433

(1) The rate represents the weighted-average interest rate as of June September 30, 2026.

2 unchanged paragraphs

Requirement Level at June September 30, 2026

3 unchanged paragraphs

Note 7: LEASES 19 changes

2 unchanged paragraphs

Three Months Ended June 30, Six Months Ended June 30,

Operating lease cost $ 5,590 $ 5,637 $ 11,445 $ 10,877

Interest on lease liabilities 303 285 624 573

Total finance lease cost $ 1,892 $ 2,208 $ 4,120 $ 4,354

The components of lease expense for the three and six nine months ended June September 30, 2026 and 2025 were as follows:

Three Months Ended September 30, Nine Months Ended September 30,

Operating lease cost $ 5,764 $ 5,832 $ 17,209 $ 16,709

Amortization of right-of-use assets $ 1,589 1,177 $ 1,923 1,982 $ 3,496 4,673 $ 3,781 5,763

Interest on lease liabilities 309 317 933 890

Total finance lease cost $ 1,486 $ 2,299 $ 5,606 $ 6,653

Short-term lease and variable lease costs $ 6,805 6,125 $ 5,402 5,821 $ 12,424 18,549 $ 10,250 16,071

1 unchanged paragraph

Six Nine Months Ended June September 30, 2026 2025

1 unchanged paragraph

Operating cash flows from operating leases $ 11,361 17,167 $ 10,730 16,732

Operating cash flows from finance leases 707 625 1,054 986

Financing cash flows from finance leases 1,905 1,720 2,877 2,700

1 unchanged paragraph

Operating leases $ 4,853 $ 6,814

Finance leases 177 360

Operating leases $ 8,613 $ 11,248

Finance leases 1,125 3,394

Note 8: RETIREMENT AND DEFERRED COMPENSATION PLANS 28 changes

Effective January 1, 2021, our domestic noncontributory retirement plans were closed to new employees and employees who were rehired after December 31, 2020. These employees are instead eligible for additional contributions to their defined contribution 401(k) employee savings plan. All domestic employees with hire/rehire dates prior to January 1, 2021 are still eligible for the domestic pension plans and continue to accrue plan benefits after this date.

We have various noncontributory retirement plans covering certain of our domestic and foreign employees. Benefits under our retirement plans are based on participants years of service and annual compensation as defined by each plan. Annual cash contributions to fund pension costs accrued under Our domestic defined benefit pension plans are generally at least equal closed to the minimum funding amounts required by the Employee Retirement Income Security Act of 1974, as amended ( ERISA ). Certain pension commitments new participants, however, eligible existing participants continue to accrue benefits under our foreign the plans. are also funded according to local requirements or at our discretion.

2 unchanged paragraphs

Service cost $ 1,986 $ 1,983 $ 1,572 $ 1,682

Interest cost 2,495 2,391 1,087 971

Net periodic benefit cost $ 1,218 $ 1,066 $ 2,224 $ 2,377

Three Months Ended June September 30, 2026 2025 2026 2025

Service cost $ 1,987 $ 1,983 $ 1,549 $ 1,732

Interest cost 2,494 2,390 1,055 999

Expected return on plan assets ( 3,260 ) ( 3,186 ) ( 608 613 ) ( 613 631 )

Amortization of net (gain) loss ( 3 4 ) ( 122 ) 145 312 34 322

Amortization of prior service cost 28 25 25

Net periodic benefit cost $ 1,217 $ 1,065 $ 2,050 $ 2,447

Curtailment ( 3,254 )

Total Net periodic benefit cost $ 1,217 $ 1,065 $ ( 1,204 ) $ 2,447

1 unchanged paragraph

Service cost $ 3,973 $ 3,966 $ 3,154 $ 3,247

Interest cost 4,989 4,782 2,181 1,873

Expected return on plan assets ( 6,520 ) ( 6,372 ) ( 1,221 ) ( 1,183 )

Six Nine Months Ended June September 30, 2026 2025 2026 2025

Service cost $ 5,960 $ 5,949 $ 4,703 $ 4,979

Interest cost 7,483 7,172 3,236 2,872

Expected return on plan assets ( 9,780 ) ( 9,558 ) ( 1,834 ) ( 1,814 )

1 unchanged paragraph

Net periodic benefit cost $ 2,435 $ 2,132 $ 4,450 $ 4,588

Amortization of prior service cost 55 48 80 73

Net periodic benefit cost $ 3,652 $ 3,197 $ 6,500 $ 7,035

Curtailment ( 3,254 )

Total Net periodic benefit cost $ 3,652 $ 3,197 $ 3,246 $ 7,035

During the third quarter of 2026, the Company recognized a $ 3.3 million curtailment gain related to the transfer of a participant from a foreign defined benefit pension plan to a U.S. retirement plan in connection with the participant s transition to a U.S.-based role. The components of net periodic benefit cost, other than the service cost component, are included in the line miscellaneous income (expense), net in the Condensed Consolidated Statements of Income.

1 unchanged paragraph

Although we have no minimum funding requirement, discretionary cash contributions to fund pension costs accrued under our domestic plans are generally at least equal to the minimum funding amounts required by ERISA. There were no contributions to our domestic defined benefit plans during the six nine months ended June September 30, 2026, and we do not expect that we will make significant additional contributions in the remainder of 2026. For the supplemental executive retirement plan (SERP), $ 0.3 0.7 million of company-paid benefits were distributed during the six nine months ended June September 30, 2026, and approximately $ 0.5 0.2 million is expected to be paid during the rest of 2026. Contributions to fund pension costs accrued under our foreign plans are made in accordance with local laws or, if not otherwise stated, at our discretion. We contributed $ 0.9 1.4 million to our foreign defined benefit plans during the six nine months ended June September 30, 2026 and do not expect to make any additional significant contributions during the rest of 2026.

Note 9: ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME 30 changes

3 unchanged paragraphs

Other comprehensive income (loss) before reclassifications 241,337 114 ( 18,005 ) 223,446

Balance - June 30, 2025 $ ( 184,712 ) $ 5,917 $ ( 26,953 ) $ ( 205,748 )

Other comprehensive income (loss) before reclassifications 237,788 344 ( 16,590 ) 221,542

Amounts reclassified from accumulated other comprehensive income 281 281 438 438

Net current-period other comprehensive income (loss) 241,337 395 237,788 782 ( 18,005 16,590 ) 223,727 221,980

Balance - September 30, 2025 $ ( 188,261 ) $ 6,304 $ ( 25,538 ) $ ( 207,495 )

1 unchanged paragraph

Other comprehensive (loss) income before reclassifications ( 30,536 ) 3,409 5,956 ( 21,171 )

Net current-period other comprehensive (loss) income ( 30,536 ) 3,637 5,956 ( 20,943 )

Balance - June 30, 2026 $ ( 210,427 ) $ 21,715 $ ( 18,613 ) $ ( 207,325 )

Other comprehensive (loss) income before reclassifications ( 50,191 ) 3,505 8,490 ( 38,196 )

Amounts reclassified from accumulated other comprehensive income 228 228 259 259

Reclassification to earnings related to Russia deconsolidation 18,658 18,658

Net current-period other comprehensive (loss) income ( 31,533 ) 3,764 8,490 ( 19,279 )

Balance - September 30, 2026 $ ( 211,424 ) $ 21,842 $ ( 16,079 ) $ ( 205,661 )

4 unchanged paragraphs

Three Months Ended June September 30, 2026 2025

1 unchanged paragraph

( 51 ) ( 66 ) Tax impact

Amortization of net loss $ 142 30 $ 190 200 (1)

Amortization of prior service cost 28 25 25 (1)

170 215 55 225 Total before tax

( 24 ) ( 68 ) Tax impact

$ 119 31 $ 149 157 Net of tax

Total reclassifications for the period $ 119 31 $ 149 157

3 unchanged paragraphs

Six Nine Months Ended June September 30, 2026 2025

1 unchanged paragraph

( 101 ) ( 126 ) Tax impact

Amortization of net loss $ 274 304 $ 359 559 (1)

Amortization of prior service cost 55 48 80 73 (1)

329 407 384 632 Total before tax

( 125 ) ( 194 ) Tax impact

$ 228 259 $ 281 438 Net of tax

Total reclassifications for the period $ 228 259 $ 281 438

1 unchanged paragraph

Note 10: DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES 28 changes

4 unchanged paragraphs

The Company enters into cross-currency swap contracts to hedge its net investment in euro-denominated assets against future volatility in the exchange rate between the U.S. dollar and the euro. As of June September 30, 2026, Aptar had cross-currency swap contracts with an aggregate notional amount of 350 million ($ 379.7 379.5 million), including 150 million ($ 176.2 million) of swaps entered into during the second quarter of 2026. These instruments are designated as net investment hedges and we elected the spot method. Gains and losses arising from the fair value adjustments of the cross-currency swap agreements are recorded in accumulated other comprehensive (loss) income as the swaps are effective in hedging the designated risk. Our cross-currency swap contracts expire at various dates through September 2029. As of June September 30, 2026, the fair value of the cross currency swap contracts was a $ 24.7 21.3 million liability.

As of June September 30, 2026, we have recorded the fair value of foreign currency forward exchange contracts of $ 0.6 1.4 million in prepaid and other and $ 1.0 0.9 million in accounts payable, accrued and other liabilities on the Condensed Consolidated Balance Sheets. All forward exchange contracts outstanding as of June September 30, 2026 had an aggregate notional contract amount of $ 141.4 108.1 million.

Fair Value of Derivative Instruments in the Condensed Consolidated Balance Sheets as of June September 30, 2026 and December 31, 2025

June September 30, 2026 December 31, 2025

1 unchanged paragraph

Foreign Exchange Contracts Prepaid and other $ $ 625 1,352 $ $ 298

1 unchanged paragraph

(1) This cross-currency swap agreement has a foreign exchange component.

Foreign Exchange Contracts Accounts payable, accrued and other liabilities $ $ 1,045 892 $ $ 632

Cross-Currency Swap Contract (1) Deferred and other non-current liabilities (1) This cross-currency swap agreement has a foreign exchange component.

The Effect of Derivatives Designated as Hedging Instruments on Accumulated Other Comprehensive Income (Loss) for the Three Months Ended June September 30, 2026 and 2025

5 unchanged paragraphs

Foreign exchange component $ 1,890 $ ( 14,138 ) Miscellaneous, net $ $ $ ( 802 )

Foreign exchange component $ 2,534 $ 1,415 Miscellaneous, net $ $ $ ( 2,889 )

The Effect of Derivatives Designated as Hedging Instruments on Accumulated Other Comprehensive Income (Loss) for the Six Nine Months Ended June September 30, 2026 and 2025

7 unchanged paragraphs

Foreign exchange component $ 5,956 $ ( 18,005 ) Miscellaneous, net $ $ $ ( 855 )

Foreign exchange component $ 8,490 $ ( 16,590 ) Miscellaneous, net $ $ $ ( 3,744 )

The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Three Months Ended June September 30, 2026 and 2025 as Hedging Instruments Location of (Loss) Gain Recognized in Income on Derivatives Amount of (Loss) Gain on Derivatives

1 unchanged paragraph

Miscellaneous, net $ 122 $ ( 496 )

Miscellaneous, net $ 849 $ ( 758 )

The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Six Nine Months Ended June September 30, 2026 and 2025 as Hedging Instruments Location of (Loss) Gain Recognized in Income on Derivatives on Derivatives

1 unchanged paragraph

Miscellaneous, net $ ( 131 ) $ 25

Miscellaneous, net $ 718 $ ( 733 )

2 unchanged paragraphs

Derivative Assets $ 625 $ 625 $ 625

Total Assets $ 625 $ 625 $ 625

Derivative Liabilities $ 25,699 $ 25,699 $ 25,699

Total Liabilities $ 25,699 $ 25,699 $ 25,699

Derivative Assets $ 1,352 $ 1,352 $ 1,352

Total Assets $ 1,352 $ 1,352 $ 1,352

Derivative Liabilities $ 22,189 $ 22,189 $ 22,189

Total Liabilities $ 22,189 $ 22,189 $ 22,189

4 unchanged paragraphs

Note 11: FAIR VALUE 7 changes

4 unchanged paragraphs

As of June September 30, 2026, the fair values of our financial assets and liabilities were categorized as follows:

4 unchanged paragraphs

Total assets at fair value $ 7,840 7,556 $ 2,215 1,204 $ 625 1,352 $ 5,000

3 unchanged paragraphs

Total liabilities at fair value $ 25,952 $ $ 25,699 $ 253

Total liabilities at fair value $ 22,442 $ $ 22,189 $ 253

13 unchanged paragraphs

The carrying amounts of our other current financial instruments such as cash and equivalents, accounts and notes receivable, notes payable and current maturities of long-term obligations approximate fair value due to the short-term maturity of the instruments. We consider our long-term debt obligations a Level 2 liability and utilize the market approach valuation technique based on interest rates that are currently available to us for issuance of debt with similar terms and maturities. The estimated fair value of our long-term obligations was $ 1.06 0.93 billion and $ 1.09 billion as of June September 30, 2026 and December 31, 2025, respectively.

As part of the Sommaplast acquisition, we are also obligated to pay the shareholders of Sommaplast certain contingent consideration based on 2025 and 2026 cumulative financial performance metrics as defined in the purchase agreement. We consider these obligations a Level 3 liability. Based on a projection as of the acquisition date, we estimated the aggregate fair value for this contingent consideration arrangement upon acquisition to be $ 4.0 million utilizing a Monte Carlo valuation model. As of June September 30, 2026, approximately $ 3.7 3.8 million of this contingent consideration has been paid out.

2 unchanged paragraphs

Balance, June September 30, 2026 $ 253

Legal proceedings 627 changes

On March 25, 2025, AptarGroup, Inc. and its subsidiary, Aptar France SAS, filed a lawsuit in the United States District Court for the Southern District of New York against ARS Pharmaceuticals, Inc. and ARS Pharmaceuticals Operations, Inc. (together, ARS ), The complaint alleges alleging that ARS misappropriated Aptar s trade secrets and breached multiple contractual confidentiality obligations Aptar seeks and seeking injunctive relief and damages. On June 12, 2025, ARS filed a motion to dismiss the complaint, which, on March 30, 2026, the court denied in substantial part and granted in part, specifically in regard to Aptar's state law trade secret misappropriation claim. On April 29, 2026, Aptar moved for leave to amend its complaint to reassert that claim, which the Court granted on June 17, 2026. ARS filed its answer to the amended complaint on July 6, 2026; it did not file any counterclaims against Aptar. This matter is pending and it is currently in the discovery stage. Relatedly, on September 29, 2025, ARS filed a lawsuit in the United States District Court for the Southern District of California against Aptar, The complaint alleges alleging that Aptar violated Sections 1 and 2 of the Sherman Act and Section 3 of the Clayton Act by refusing to sell certain components ARS seeks and seeking injunctive relief and damages. On December 16, 2025, Aptar filed a motion to dismiss the ARS complaint, or to transfer the complaint to These two matters have now been consolidated in the Southern District of New York, ARS opposed are pending and no final determination has been made by the motion court. On January 27, October 14, 2026, and Aptar filed its reply on February 27, 2026. On July 17, 2026, the Court transferred the matter to the Southern District of New York; it did not address the a motion to dismiss. At this stage, this matter is too preliminary amend the complaint, to form a judgment add Silgan Dispensing Systems Corp. as to whether an adverse outcome is probable, and we are unable a party to estimate the possible loss or range of loss, if any. case. The motion is pending.

In May 2025, Nemera La Verpilli re SAS ("Nemera") filed parallel patent infringement actions in Mannheim Regional Court, Germany (the "Mannheim Court") and Paris Judicial Court, France against Aptar and certain subsidiaries alleging that Aptar's ophthalmic product infringes a Nemera patent, seeking an injunction and damages. Aptar is contesting the claims and the proceedings are continuing. Aptar filed oppositions before the European Patent Office ("EPO") challenging the validity of the European Patent (EP) asserted by Nemera On October 2, 2025, an EPO hearing invalidated Nemera s main patent claim while allowing an amended claim to continue. Following further EPO proceedings in February 2026, certain asserted claims were dismissed and an amended claim was allowed; both parties filed appeals of the decision, which are still pending The Mannheim Court held with a further hearing scheduled for May 2027. In addition, on the August 7, 2026, Aptar Radolfzell GmbH has brought a patent infringement action on June 23, 2026 and a decision is expected on August 11, 2026. against Nemera La Verpilli re SAS before the trial in Unified Patent Court, Paris Local Division of the French proceeding is scheduled for January 2027. Aptar will continue to monitor developments related Court of First Instance, relating to this matter and evaluate the potential impact, if any, on its Condensed Consolidated Financial Statements. Nemera's ophthalmic dispensers.

At this stage, each of the above matters is too preliminary to form a judgment as to whether an adverse outcome is probable, and we are unable to estimate the possible loss or range of loss, if any.

1 unchanged paragraph

On February 20, 2026, the United States Supreme Court ruled that the International Emergency Economic Powers Act ( IEEPA ) does not authorize the imposition of tariffs. thereby invalidating tariffs previously imposed by the US administration under that statute. Subsequent to the decision, a new tariff surcharge of at least 10% was imposed on most imports under Section 122 of the Trade Act of 1974, effective on February 24, 2026, for a period of up to 150 days.

Following the ruling, the U.S. Court of International Trade directed U.S. Customs and Border Protection to finalize or revise certain import transactions without applying IEEPA based tariffs and is overseeing the development of a refund process. Aptar has historically paid IEEPA-based duties and is evaluating the applicability of these decisions to its import entries, including procedural requirements under U.S. customs law. In accordance with ASC 450 30, Contingencies Gain Contingencies, Aptar will account for any potential recovery of previously paid IEEPA tariffs as a gain contingency. As of June 30, 2026, Aptar has received certain tariff refunds and continues to evaluate additional potential recoveries; however, such amounts were not material to our Condensed Consolidated Financial Statements.

On February 20, 2026, the United States Supreme Court ruled that the International Emergency Economic Powers Act ( IEEPA ) does not authorize the imposition of tariffs. thereby invalidating tariffs previously imposed by the US administration under that statute. Effective July 24, 2026, the new Section 301 Forced Labor tariffs replaced the expired Section 122 tariff program. The new section 310 tariff framework applies country-specific tariff rates ranging from 10% to 12.5%, while preserving exemptions for USMCA-qualified goods and certain products already subject to Section 232 tariffs. Through our preliminary analysis, we do not expect that the new Section 301 tariff will have significant incremental impact to Aptar.

During Q3 2026, Aptar continues to submit IEEPA tariff refund claims through CBP's CAPE platform using a phased approach based on entry expiration dates and data readiness. In accordance with ASC 450 30, Contingencies Gain Contingencies, Aptar will account for any potential recovery of previously paid IEEPA tariffs as a gain contingency. As of September 30, 2026, Aptar has received certain tariff refunds and continues to evaluate additional potential recoveries; no amounts have been recognized for such additional potential recoveries.

Under our Certificate of Incorporation, we have agreed to indemnify our officers and directors for certain events or occurrences while the officer or director is, or was, serving at our request in such capacity. The maximum potential amount of future payments we could be required to make under these indemnification agreements is unlimited; however, we have a directors and officers liability insurance policy that covers a portion of our exposure. As a result of our insurance policy coverage, we believe the estimated fair value of these indemnification agreements is minimal. We have no liabilities recorded for these agreements as of June September 30, 2026 and December 31, 2025.

We are periodically subject to loss contingencies resulting from customs duties assessments. We accrue for anticipated costs when an assessment has indicated that a loss is probable and can be reasonably estimated. We have received claims worth approximately $ 10.0 11.0 million to $ 11.0 12.0 million in principal, and $ 21.0 22.0 million to $ 22.0 23.0 million for interest and penalties. We are currently defending our position with respect to these claims in the respective administrative procedures. Due to uncertainty in the probability of settlement and the timing of our appeal, no liability is recorded as of June September 30, 2026.

We will continue to evaluate these liabilities periodically based on available information, including the progress of remedial investigations, the status of discussions with regulatory authorities regarding the methods and extent of remediation and the apportionment of costs and penalties among potentially responsible parties.

2 unchanged paragraphs

During the three and six nine months ended June September 30, 2026, we repurchased approximately 403 234 thousand shares for $ 50.0 30.0 million and 1.1 1.3 million shares for $ 150.0 180.0 million, respectively. During the three and six nine months ended June September 30, 2025, we repurchased approximately 452 286 thousand shares for $ 70.0 40.0 million and 1.0 1.3 million shares for $ 150.0 190.0 million, respectively. As of June September 30, 2026, there was $ 450.0 420.0 million for authorized share repurchases remaining under the existing authorization.

5 unchanged paragraphs

Six Nine Months Ended June September 30, 2026 2025

7 unchanged paragraphs

A summary of RSU activity as of June September 30, 2026 and changes during the six nine month period then ended is presented below:

5 unchanged paragraphs

Granted 136,403 119.93 221,051 120.85

Vested ( 104,004 ) 131.04 ( 198,125 ) 116.17

Forfeited ( 4,056 ) 143.16 ( 43,303 ) 110.19

Nonvested at June 30, 2026 243,776 $ 128.77 414,501 $ 139.37

Compensation expense, Total $ 18,220 $ 21,581

Granted 146,343 120.23 229,998 120.95

Vested ( 106,420 ) 131.10 ( 198,125 ) 116.17

Forfeited ( 6,901 ) 131.80 ( 47,235 ) 111.46

Nonvested at September 30, 2026 248,455 $ 128.67 419,516 $ 139.16

Included in the time-based RSU activity for the six nine months ended June September 30, 2026 are 12,160 13,594 units granted to non-employee directors and 9,805 units that vested related to non-employee directors.

Six Nine Months Ended June September 30, 2026 2025

Compensation expense (included in SG&A) $ 16,596 23,902 $ 19,734 27,515

Compensation expense (included in Cost of sales) 1,624 1,847 2,269 2,588

Compensation expense, Total $ 26,171 $ 30,103

Fair value of units vested 35,035 41,854 35,358 43,382

Intrinsic value of units vested 37,464 51,645 37,772 53,743

The actual tax benefit realized for the tax deduction from RSUs was approximately $ 6.7 6.8 million and $ 9.3 9.8 million in the six nine months ended June September 30, 2026 and 2025, respectively. As of June September 30, 2026, there was $ 52.6 45.4 million of total unrecognized compensation cost relating to RSU awards which is expected to be recognized over a weighted-average period of 2.0 1.8 years.

1 unchanged paragraph

Aptar uses historical data to estimate expected life and volatility. The weighted-average fair value of stock options granted under the stock awards plans was $ 31.93 and $ 36.91 per share during the first six nine months of 2026 and 2025, respectively. These values were estimated on the respective dates of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:

Six Nine Months Ended June September 30, 2026 2025

4 unchanged paragraphs

A summary of option activity under our stock plans during the six nine months ended June September 30, 2026 is presented below:

2 unchanged paragraphs

Granted 273,795 123.97

Exercised ( 255,829 ) 74.20

Forfeited or expired ( 8,813 ) 121.96

Outstanding at June 30, 2026 1,617,651 $ 111.45

Exercisable at June 30, 2026 1,124,692 $ 101.77

Granted 283,326 124.20

Exercised ( 298,136 ) 75.01

Forfeited or expired ( 9,813 ) 123.47

Outstanding at September 30, 2026 1,583,875 $ 112.39

Exercisable at September 30, 2026 1,081,669 $ 102.61

1 unchanged paragraph

Outstanding at June September 30, 2026 5.4 5.3

Exercisable at June September 30, 2026 3.7 3.6

1 unchanged paragraph

Outstanding at June 30, 2026 $ 30,753

Exercisable at June 30, 2026 $ 30,417

June 30, 2026 $ 13,704

June 30, 2025 $ 10,628

Compensation expense, Total $ 5,852 $ 5,626

Outstanding at September 30, 2026 $ 26,744

Exercisable at September 30, 2026 $ 26,744

Intrinsic Value of Options Exercised During the Six Nine Months Ended:

September 30, 2026 $ 15,962

September 30, 2025 $ 15,079

Six Nine Months Ended June September 30, 2026 2025

Compensation expense (included in SG&A) $ 5,392 6,305 $ 5,139 6,082

Compensation expense (included in Cost of sales) 460 487 567 587

Compensation expense, Total $ 6,872 $ 6,669

Compensation expense, net of tax 4,982 4,656 5,776 5,455

1 unchanged paragraph

The increase in stock option expense is due to the newly issued options as discussed above. Cash received from option exercises for the six nine months ended June September 30, 2026 and 2025 was approximately $ 19.0 22.4 million and $ 10.6 14.9 million, respectively. The actual tax benefit realized for the tax deduction from option exercises was approximately $ 3.2 3.7 million and $ 2.6 3.8 million in the six nine months ended June September 30, 2026 and 2025, respectively. As of June September 30, 2026, there was $ 7.2 6.2 million of total unrecognized compensation cost relating to stock option awards which is expected to be recognized over a weighted-average period of 2.1 2.0 years.

1 unchanged paragraph

Basic net income per share is calculated by dividing net income attributable to Aptar by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income attributable to Aptar by the weighted-average number of common and common equivalent shares outstanding during the applicable period. The difference between basic and diluted earnings per share is attributable to stock-based compensation awards. Stock-based compensation awards for which total employee proceeds exceed the average market price over the applicable period would have an antidilutive effect on earnings per share, and accordingly, are excluded from the calculation of diluted earnings per share. The reconciliation of basic and diluted earnings per share for the three and six nine months ended June September 30, 2026 and 2025 were as follows:

June September 30, 2026 June September 30, 2025

2 unchanged paragraphs

Income available to common stockholders $ 87,573 $ 87,573 $ 111,720 $ 111,720

Income available to common stockholders $ 32,602 $ 32,602 $ 127,927 $ 127,927

1 unchanged paragraph

Shares of common stock 63,634 63,634 65,995 65,995

Shares of common stock 63,523 63,523 65,709 65,709

1 unchanged paragraph

Stock options 224 568

Restricted stock 350 485

Total average equivalent shares 64,208 63,634 67,048 65,995

Net income per share $ 1.36 $ 1.38 $ 1.67 $ 1.69

Stock options 260 491

Restricted stock 364 430

Total average equivalent shares 64,147 63,523 66,630 65,709

Net income per share $ 0.51 $ 0.51 $ 1.92 $ 1.95

June September 30, 2026 June September 30, 2025

2 unchanged paragraphs

Income available to common stockholders $ 160,247 $ 160,247 $ 190,518 $ 190,518

Income available to common stockholders $ 192,849 $ 192,849 $ 318,445 $ 318,445

1 unchanged paragraph

Shares of common stock 63,841 63,841 66,132 66,132

Shares of common stock 63,733 63,733 65,989 65,989

1 unchanged paragraph

2 unchanged paragraphs

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

3 unchanged paragraphs

1 unchanged paragraph

4 unchanged paragraphs

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

3 unchanged paragraphs

2 unchanged paragraphs

2 unchanged paragraphs

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

2 unchanged paragraphs

1 unchanged paragraph

2 unchanged paragraphs

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

2 unchanged paragraphs

2 unchanged paragraphs

2 unchanged paragraphs

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

2 unchanged paragraphs

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

2 unchanged paragraphs

2 unchanged paragraphs

3 unchanged paragraphs

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

2 unchanged paragraphs

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

2 unchanged paragraphs

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

1 unchanged paragraph

3 unchanged paragraphs

1 unchanged paragraph

and 547 more changes in the filing

Forward-looking statements 3 changes

4 unchanged paragraphs

geopolitical conflicts worldwide and the resulting indirect impact on demand from our customers selling their products into these countries, and certain supply chain disruptions, as well as governmental actions affecting our foreign operations and assets, including the loss of control over, and our ability to recover value from, our Russian operations;

6 unchanged paragraphs

significant tariffs and other restrictions on foreign imports imposed by the U.S. and related countermeasures are taken by impacted foreign countries;

9 unchanged paragraphs

changes in capital availability or cost, including rising interest rates; rate volatility;

17 unchanged paragraphs

Market risk 42 changes

1 unchanged paragraph

The table below provides information as of June September 30, 2026 about our forward currency exchange contracts. The increase in USD/MXN and MXN/USD notional amounts reflect forward-starting foreign currency swaps entered into during the quarter. The tabular presentation includes both the near and far legs of these contracts in accordance with the Company's market risk disclosure methodology. The majority of the contracts expire before the end of the third fourth quarter of 2026.

3 unchanged paragraphs

USD / MXN $ 44,000 17.7222 31,000 - 49,000

EUR / USD 27,486 1.1642 27,486 - 33,688

MXN / USD 14,700 0.0573 0 - 22,200

EUR / BRL 9,666 6.0998 9,666 - 9,997

CZK / EUR 9,158 0.0411 6,843 - 9,158

CHF / EUR 7,469 1.0904 636 - 7,469

EUR / CHF 5,260 0.9188 4,291 - 5,260

INR / EUR 5,142 0.0090 0 - 5,142

USD / EUR 4,285 0.8611 4,285 - 6,108

EUR / INR 4,225 113.0352 0 - 4,225

EUR / MXN 2,857 20.9366 2,857 - 3,503

EUR / THB 2,724 37.8925 2,593 - 2,724

GBP / EUR 1,039 1.1511 898 - 1,374

EUR / GBP 848 0.8674 438 - 1,824

CHF / USD 844 1.2756 702 - 1,049

USD / INR 716 97.1439 0 - 716

CZK / USD 320 0.0479 120 - 320

EUR / CZK 255 24.3573 255 - 633

USD / GBP 231 0.7470 231 - 330

USD / CHF 100 0.7902 100 - 338

GBP / USD 58 1.3458 0 - 182

USD / MXN $ 35,000 17.5994 35,000 - 38,500

EUR / USD 22,810 1.1533 22,810 - 40,608

and 18 more changes in the filing

Controls and procedures 2 changes

1 unchanged paragraph

1 unchanged paragraph

and 2 more changes in the filing

Unregistered sales of stock 5 changes

1 unchanged paragraph

2 unchanged paragraphs

1 unchanged paragraph

and 5 more changes in the filing

Other information 1 change

1 unchanged paragraph

and 1 more change in the filing

Exhibits 4 changes

4 unchanged paragraphs

6 unchanged paragraphs

and 4 more changes in the filing